Xencor (XNCR) Amortization of Deferred Charges (2023 - 2026)
Xencor (XNCR) reported Amortization of Deferred Charges of $4.7 million for Q1 2026, down 45.75% year-over-year from $8.7 million in Q1 2025, and down 36.07% quarter-over-quarter from $7.4 million in Q4 2025.
Xencor (XNCR) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
Xencor (XNCR) has 4 years of Amortization of Deferred Charges data on file, last reported at $4.7 million in Q1 2026.
- Amortization of Deferred Charges for Q1 2026 came in at $4.7 million, down 45.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.0 million (down 21.45% YoY), and the FY2025 annual result was $31.9 million, down 12.77% from the prior year.
- Amortization of Deferred Charges eased to $4.7 million in Q1 2026 per XNCR's latest filing, from $7.4 million in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $9.7 million in Q1 2024 and troughed at $4.7 million in Q1 2026.
- A 4-year average of $7.9 million and a median of $8.4 million in 2024 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2024 and 2026: Amortization of Deferred Charges soared 40.47% in 2024, then slumped 45.75% in 2026.
- A 4-year view of Amortization of Deferred Charges shows it stood at $6.2 million in 2023, then surged by 40.47% to $8.6 million in 2024, then retreated by 14.94% to $7.4 million in 2025, then plunged by 36.07% to $4.7 million in 2026.
- Business Quant data shows XNCR's Amortization of Deferred Charges at $4.7 million in Q1 2026, $7.4 million in Q4 2025, and $7.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.70 Mn |
| Mar 31, 2026 | 4.70 Mn |
| Dec 31, 2025 | 7.35 Mn |
| Dec 31, 2025 | 7.35 Mn |
| Sep 30, 2025 | 7.66 Mn |
| Sep 30, 2025 | 7.66 Mn |
| Jun 30, 2025 | 8.24 Mn |
| Jun 30, 2025 | 8.24 Mn |
| Mar 31, 2025 | 8.66 Mn |
| Mar 31, 2025 | 8.66 Mn |
| Dec 31, 2024 | 8.64 Mn |
| Dec 31, 2024 | 8.64 Mn |
| Sep 30, 2024 | 9.01 Mn |
| Sep 30, 2024 | 9.01 Mn |
| Jun 30, 2024 | 9.27 Mn |
| Jun 30, 2024 | 9.27 Mn |
| Mar 31, 2024 | 9.67 Mn |
| Mar 31, 2024 | 9.67 Mn |
| Dec 31, 2023 | 6.15 Mn |
| Dec 31, 2023 | 6.15 Mn |